ESMO20: New first-line treatment option for metastatic kidney cancer

Toni K. Choueiri | ESMO 2020 | Onkologi /hematologi | September 24, 2020

Speaker: Toni K. Choueiri

The results of the phase 3 CheckMate 9ER trial have provided a new first line treatment option for patients with metastatic kidney cancer. In this MEDtalk, Toni K. Choueiri , Director, The Lank Center for Genitourinary, Oncology, Dana-Farber Cancer Institute, and professor of Harvard Medical School, Boston, USA, presents the data for the combinations therapy of nivolumab and cabozantinib against standard of care, sunitinib.

MD Toni K. Choueiri Professor of Medicine, Harvard Medical School, Director of Genitourinary (GU) Oncology Disease Center & Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute